Search for European Projects

18 European Projects Found

Searched on 125080 European Projects

 FINISHED 

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)

Start date: Jan 1, 2016, End date: Dec 31, 2020,

Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Read Project

 43

 FINISHED 

Paediatric Inflammatory Bowel Diseases Network for Safety, Efficacy, Treatment and Quality improvement of care (PIBD-SETQuality)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

"The incidence of paediatric onset Inflammatory Bowel Diseases (PIBD) has risen dramatically in recent decades. Compared to adult forms, PIBD reflects a more severe disease, more often requiring aggressive treatment with immunomodulators, and thereby exposing children to a life-long risk of serious disease and treatment-related adverse events, such as infections and malignancies. Therefore, there ...
Read Project

 12

 FINISHED 

Advance Care Planning; an Innovative Palliative Care Intervention to Improve Quality of Life in Cancer Patients - a Multi-Centre Cluster Randomized Clinical Trial (ACTION)

Start date: Dec 1, 2013, End date: Nov 30, 2018,

"Advanced cancer typically involves multiple symptoms and seriously affects patients´ quality of life. Anxiety and depression are common. Medical care for patients with advanced cancer should be aimed at symptom control, psychosocial support, spiritual needs, and practical issues. Patients’ preferences regarding care should be central. Open and respectful communication are of key importance, but h ...
Read Project

 8

 FINISHED 

Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex (EPISTOP)

Start date: Nov 1, 2013, End date: Oct 31, 2018,

Despite a great progress in the management of epilepsy, still one third of patients is refractory to available medications. The incidence of epilepsy is highest in infancy and 50% of children experience epilepsy-related comorbidities, such as developmental delay and autism. The development of epilepsy (epileptogenesis), extensively studied in animals, is barely studied in humans, as patients usual ...
Read Project

 16

 FINISHED 

Development of in vitro and in vivo strategies to avoid and cure male infertility (GROWSPERM)

Start date: May 1, 2014, End date: Apr 30, 2018,

"In many European countries at least 20% of young men exhibit sperm parameters below the lower WHO reference level and this will affect their fertility. Male infertility has a dramatic impact on the individual and couple’s psychological and social well-being and results in significant healthcare costs. Currently male patients that do not produce sperm have no therapeutic options to father children ...
Read Project

 7

 FINISHED 

Therapeutic TriMix / mRNA based Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral Therapy (IHIVARNA)

Start date: Dec 1, 2013, End date: Nov 30, 2017,

To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be the best option. We have reported in a double-blind placebo controlled study some of the best, most solid data showing that HIV-1 specific immune responses elicited by therapeutic dendritic cell (DC) vaccines pulsed ex vivo with inactivated autologous whole vir ...
Read Project

 8

 FINISHED 

Long-term effects of early nutrition on later health (EARLYNUTRITION)

Start date: Feb 1, 2012, End date: Oct 31, 2017,

Nutrition during early development has an important impact on later health, particularly through greater obesity risk, as demonstrated by FP6 EARNEST. EarlyNutrition explores the current key hypotheses on likely causes and pathways to prevention of early life origins of obesity (specifically adiposity) and associated disorders. We bring extraordinary expertise and study populations of 470,000 indi ...
Read Project

 40

 FINISHED 

Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)

Start date: May 1, 2012, End date: Oct 30, 2017,

Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Read Project

 23

 FINISHED 

The MEtabolic Road to DIAstolic Heart Failure (MEDIA)

Start date: Jan 1, 2011, End date: Jun 30, 2016,

More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements c ...
Read Project

 23

 FINISHED 

Effective Communication in Outbreak Management: development of an evidence-based tool for Europe (E-COM@EU)

Start date: Feb 1, 2012, End date: Jan 31, 2016,

Although scientific knowledge to respond to outbreaks has increased, deficiencies remain in the ability of health authorities to communicate the need for large-scale measures such as vaccination and antiviral therapy and increase its acceptance. For effective behavioural and communication strategies, integration is needed of social, behavioural, communication and media sciences.We bring together t ...
Read Project

 13

 FINISHED 

Building data bridges between biological and medical infrastructures in Europe (BIOMEDBRIDGES)

Start date: Jan 1, 2012, End date: Dec 31, 2015,

The ESFRI infrastructures in Biological and BioMedical Sciences face substantial challenges in accessing and sharing data and resources. The BioMedBridges consortium brings together the six established ESFRI infrastructures with common goals to define, implement and deliver data interoperability across the biological and biomedical domains.The first objective is to ensure that interoperable stand ...
Read Project

 26

 FINISHED 

EVALUATING THE IMPACT OF STRUCTURAL POLICIES ON HEALTH INEQUALITIES AND THEIR SOCIAL DETERMINANTS AND FOSTERING CHANGE (SOPHIE)

Start date: Nov 1, 2011, End date: Oct 31, 2015,

The need to deal with health inequalities is now on the agenda of key supranational institutions, such as the European Commission (EC). To tackle the so-called “causes of the causes of health inequity”, the focus should be put on structural policies, policies that – especially in the current times of financial and employment crisis – influence patterns of social stratification, living and working ...
Read Project

 14

 FINISHED 

Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)

Start date: Oct 1, 2011, End date: Sep 30, 2015,

"In 2010 a widely marketed drug for the treatment of type 2 diabetes (T2DM) (rosiglitazone) was taken from the market as it was associated with an increased risk of myocardial infarction, a T2DM complication it was actually supposed to prevent. This example shows several things. First, the approval requirements do not guarantee a longer term positive benefit risk profile. Second, large scale postm ...
Read Project

 19

 FINISHED 

Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance (OVER-MYR)

Start date: Jan 1, 2012, End date: Jun 30, 2015,

Multiple Myeloma (MM) is a currently incurable rare malignant plasma cell disease, which invariably relapses despite therapy. The objective of OVER-MYR is to understand the causes of drug resistance and relapse, develop novel strategies to overcome these, provide proof of principal for phase I/II trial, and thus impact on MM-patient’s survival.Currently-used drugs target both MM cells (MMC) and c ...
Read Project

 11

 FINISHED 

Persisting Transgenesis (PERSIST)

Start date: Jan 1, 2009, End date: Jun 30, 2013,

"For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize ...
Read Project

 29

 FINISHED 

Novel secretion systems of Mycobacterium tuberculosis and their role in host-pathogen interaction (NOVSEC-TB)

Start date: Jan 1, 2008, End date: Jun 30, 2011,

"Tuberculosis is a major public health threat to the populations of Europe and the world. Mycobacterium tuberculosis, the etiological agent of the disease, can multiply and persist within phagocytic cells and this early event is of primary importance for the outcome of the infection. The main objectives of this proposal are to use highly innovative approaches in molecular and cell biology, biochem ...
Read Project

 8

 FINISHED 

Empowering Health Learning for Elderly

Start date: Dec 1, 2007,

The core objective of the project was to develop and test a Training System (EHLE), aimed at providing both professionals and volunteers with appropriate knowledge and tools in order to teach older people how to understand health-related information as well as healthy lifestyle messages. The outputs of the project activities were: • A Training Concept structured into 5 + 1 “knowledge modules” add ...
Read Project

 4

 FINISHED 

EUROPALS - European Pathology Assessment & Learning System

Pathology is a medical specialty that provides the histological (microscopical) diagnoses in clinical settings. Every diagnosis is made by the pathologist himself after microscopic examination of the cells and tissues that are removed from a patient, and this diagnosis is the golden standard for further decisions on treatment and prognosis. At this moment (and in the foreseeable future) there is n ...
Read Project

 31